Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
AVROBIO Inc
NASDAQ AVRO
Data sourced from
and
and
Download Data
AVROBIO Inc Price to Book Ratio (P/B) on June 03, 2024: 0.74
AVROBIO Inc Price to Book Ratio (P/B) is 0.74 on June 03, 2024, a -14.86% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.
-
AVROBIO Inc 52-week high Price to Book Ratio (P/B) is 1.01 on June 09, 2023, which is 36.46% above the current Price to Book Ratio (P/B).
-
AVROBIO Inc 52-week low Price to Book Ratio (P/B) is 0.34 on June 30, 2023, which is -53.85% below the current Price to Book Ratio (P/B).
-
AVROBIO Inc average Price to Book Ratio (P/B) for the last 52 weeks is 0.61.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: AVRO
| CEO | Mr. Geoff MacKay BSc |
| IPO Date | June 21, 2018 |
| Location | United States |
| Headquarters | Building 300, Cambridge, MA, United States, 02139 |
| Employees | 13 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Key trends
Similar companies
Hepion Pharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email